(Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration moves ahead with a 100% tariff on imported branded and patented drugs, starting October 1. The sweeping measure has triggered a flurry of activity across the industry, including fast-tracking U.S. manufacturing projects, price cuts and direct-to-consumer sales. Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors: Pfizer Pfizer re ...

Group 1 - The report emphasizes the importance of emerging technologies in addressing global challenges and shaping a sustainable future, highlighting the need for a comprehensive ecosystem for their maturity and application [1][3][36] - The report identifies ten emerging technologies for 2025, which are expected to drive significant transformations across various sectors [2][5][36] - The selection process for the emerging technologies involved expert recommendations, AI analysis, evaluation of technological maturity, and macro-strategic considerations [4] Group 2 - Structural battery composites (SBCs) integrate energy storage and structural functions, potentially revolutionizing applications in electric vehicles and aerospace [5][6][7] - Osmotic power systems utilize salinity differences to generate energy, offering a stable and low-impact renewable energy source [8][9][10] - Advanced nuclear technologies are evolving to meet increasing energy demands while supporting decarbonization efforts, with significant investments in small modular reactors (SMRs) [11][12][13] Group 3 - Engineered living therapeutics aim to produce therapeutic substances within the body, potentially overcoming traditional drug production challenges [14][15] - GLP-1 receptor agonists, initially developed for diabetes, are being explored for their neuroprotective properties in treating neurodegenerative diseases [16][17] - Autonomous biochemical sensors enable real-time monitoring of biochemical parameters, enhancing health management and environmental monitoring [18][19][20] Group 4 - Green nitrogen fixation technologies aim to reduce the carbon footprint of ammonia production, crucial for global food supply [22][23][24] - Nanozymes, synthetic materials with enzyme-like properties, are gaining attention for their potential applications in healthcare and environmental solutions [25][26][27] - Collaborative sensing technologies enhance decision-making in connected systems, with applications in urban traffic management and environmental monitoring [28][29][30] Group 5 - Generative watermarking technologies are being developed to verify the authenticity of AI-generated content, addressing concerns over misinformation and intellectual property [31][32][33] - The report highlights the need for robust governance and guidelines to ensure the effective implementation of emerging technologies [34][35]

Group 1: Granolas Sector Analysis - The Granolas sector, which includes major European companies, has underperformed the European market index by approximately 25% since early 2024, with its market capitalization dropping from 27% to 20% of the overall European market [2] - Despite weak stock performance, Granolas' earnings have not deteriorated, with an expected earnings growth rate of 8% for 2025, while overall European market earnings are projected to remain flat [2] - The valuation issues of Granolas have been corrected, with the current price-to-earnings ratio at a 6% discount compared to the median of the past 10 years, indicating a return to reasonable levels [2] - Granolas' free cash flow yield has improved, and cash reserves on the balance sheet increased from €91 billion in 2023 to €106 billion in 2024, with stock buybacks projected to rise from €23 billion in 2023 to an annualized €36 billion in 2025 [2] Group 2: French Stock Market Outlook - The French stock market has underperformed the market by about 15% over the past two years, with bank stocks lagging behind Eurozone peers by as much as 30% [4] - Currently, the French stock market is trading at a significant discount compared to the STOXX 50 index, a situation historically seen only during major crises [4] - Morgan Stanley believes that the long-term bond yields in France are unlikely to continue rising, and the negative impact from the government's failure to pass a confidence vote may temporarily dissipate, presenting attractive investment opportunities [4] - Despite high uncertainty, including potential future confidence votes, there is a possibility of reaching a budget plan acceptable to the market, and any negative impact from re-elections on risk assets may be short-lived [4]

高盛认为，新任首席执行官的首要沟通内容将是向市场保证葛兰素史克实现其长期目标的策略，尤其是 其到 2031 年实现超过 400 亿英镑销售额的销售指引，这也是新闻稿中所重申的内容。此外，高盛预计 投资者将会关注新首席执行官如何能够提升公司创新能力的相关细节。高盛认为，这对于推动该股票实 现有意义的重新估值至关重要，因为该股票一直处于同行业股票的较低水平。 智通财经APP获悉，在葛兰素史克(GSK.US)宣布更换首席执行官之后，高盛发布研报，重申对葛兰素 史克"中性"评级，目标价41美元。 9月29日，葛兰素史克公司宣布卢克·米尔斯(Luke Miels)已获任命为首席执行官候选人，并将于 2026 年 1 月 1 日正式担任首席执行官一职，接替现任首席执行官艾玛·沃尔姆斯利(Emma Walmsley)。米尔斯于 2017 年加入葛兰素史克公司，目前担任首席商业官，他在构建葛兰素史克的专科药物产品组合(尤其是 肿瘤学和呼吸系统领域)方面发挥了关键作用。在加入葛兰素史克之前，米尔斯曾在阿斯利康、罗氏和 赛诺菲等公司担任过多个高级职务。 据葛兰素史克公司称："我们注意到内部和外部候选人均曾被考虑担任这一职务。并且 ...

Financing Overview - A total of 26 financing events occurred in Shanghai this week, with Zhangjiang and Lingang each having 4 events [2][4] - 9 financing amounts were disclosed, totaling approximately 950 million yuan, which is an increase of 7 events compared to last week [4] - The Pudong New Area led with 7 financing events, followed by Minhang with 6 events, and new financing events were reported in Jing'an, Baoshan, and Xuhui [4] Company Dynamics - Yibo Semiconductor showcased at the SEMI-e 2025 Shenzhen exhibition on September 16 [3] - Aobai Xin Bio made a notable appearance at the Tianjin Nucleic Acid Conference on September 17 [3] - Jinfang Pharmaceutical was listed on the Hong Kong Stock Exchange on September 19 [5] - Changfeng Pharmaceutical passed the Hong Kong Stock Exchange listing hearing on September 23 [5] - Innovent Biologics announced the approval of its adalimumab injection in Macau on September 24 [5] - Eli Lilly announced the construction of a new pharmaceutical factory in Texas, USA, on September 24 [5] - WuXi Biologics launched an industry-leading integrated CHO cell line development platform, TrueSite TI™, on September 25 [5] - Roche's weight loss drug entered the third phase of clinical trials on September 26 [5] Hot Industry Focus - The medical health sector saw 7 financing events this week, covering areas such as chemical preparations, synthetic biology, antibody drugs, and medical consumables [26] - The capital market is active, with steady progress in the listing of biopharmaceutical companies [26] - The Shanghai government has implemented a plan to enhance the international competitiveness of biopharmaceutical companies, aiming for drug and medical device exports to exceed 50 billion yuan by the end of 2027 [26] Notable Financing Events - Yafei Bio completed nearly 300 million yuan in B++ round financing on September 23, led by Guosheng Capital [14] - Antai Micro completed several hundred million yuan in B round financing on September 26, with investors not disclosed [16] - Ailios completed over 100 million yuan in A++ round financing on September 28, led by Longpan Investment [18] - Youliqi Robot completed nearly 100 million yuan in angel +++ round financing on September 28, with multiple investors participating [20] - Chuangke Technology completed tens of millions in angel round financing on September 23, exclusively funded by Taicang Zhihui Science and Technology Innovation Fund [22] - Jidong Technology completed tens of millions in angel round financing on September 23, funded by Jijia Investment [24]

今年荣获"上海市荣誉市民"称号的李曦萌是中国丹麦商会全国创始会长及特雷通集团创始人兼首席 执行官，为促进中丹经贸领域的交流合作、推动上海发展和对外友好交往作出卓越贡献。施万是罗氏集 团董事会主席，他长期关注中国和上海的发展，推动罗氏上海创新中心、罗氏中国加速器项目在沪落 地，于2009年起连续16年参加上海市市长国际企业家咨询会议，并于2024年起担任会议主席。 此次荣获"白玉兰荣誉奖"的28位外籍人士来自美国、英国、法国、德国、澳大利亚、荷兰、新加 坡、日本等国家，在经贸、金融、科技、航运、医疗、教育、文化等领域为上海经济社会发展作出了突 出贡献。他们是：埃里克·科尼埃尔、安南、戴光辉、德里克·迪恩、范睿思、福斯特、葛思越、古睿 智、顾宇韶、贺朗瑞纳、菅匡彦、简思华、杰夫、康思大、柯曼、孔康瑞、朗智文、楼剑锋、马溯·斯 特贝尔、米歇尔·欧斯莱、诺伯特、彭振科、申安迪、肖松、谢伟博、杨葆焱、虞晶怡、约根·博乐。 记者 吴頔 洪俊杰 上海市政府昨天举行2025年"上海市荣誉市民""白玉兰荣誉奖"颁授仪式。丹麦籍人士李曦萌、瑞士 籍人士施万获"上海市荣誉市民"称号，法国籍人士埃里克·科尼埃尔等28人获"白玉兰荣誉 ...

30名外籍人士获颁2025年上海市白玉兰系列奖项 中新社上海9月29日电 (高志苗 许婧)2025年"上海市荣誉市民""白玉兰荣誉奖"颁授仪式29日在上海举 行，丹麦籍人士李曦萌、瑞士籍人士施万获"上海市荣誉市民"称号，法国籍人士埃里克·科尼埃尔等28 人获"白玉兰荣誉奖"。 2025年荣获"上海市荣誉市民"称号的李曦萌是中国丹麦商会全国创始会长、特雷通集团创始人兼首席执 行官，为促进中国和丹麦经贸领域的交流合作、推动上海发展和对外友好交往作出卓越贡献。施万是罗 氏集团董事会主席，他长期关注中国和上海的发展，推动罗氏上海创新中心、罗氏中国加速器项目在沪 落地，自2009年起连续16年参加上海市市长国际企业家咨询会议，并于2024年起担任会议主席。 李曦萌接受中新社记者采访时表示，"白玉兰精神"代表着上海对外籍人士的认可，也象征着这座城市的 开放与包容。"上海是我的家，在我居住的33年里，我深刻感受到这座城市的欢迎、开放和包容，来自 商业界、政府，尤其是来自上海人民的热情接纳。" 据了解，上海市政府自1989年起设立并形成以白玉兰为名的常设性系列综合奖项，以表彰和感谢杰出外 籍人士为上海经济建设、社会发展和对外 ...

Core Viewpoint - The recent announcement by President Trump to impose a 100% tariff on all imported brand-name or patented drugs starting October 1 has caused significant upheaval in the pharmaceutical supply chain, leading to protests from European pharmaceutical giants and concerns over rising drug prices in the U.S. [1][2] Tariff Policy Impact - The new tariff policy adds complexity to an already intricate pharmaceutical supply chain, with experts urging the White House for clearer details [2] - The 100% tariff applies to imported brand-name drugs, but companies with existing or planned manufacturing facilities in the U.S. may be exempt [2] - The exclusion of generic drugs from the tariff is notable, as they constitute a significant portion of U.S. prescription drug sales [2][3] Economic Implications - U.S. pharmaceutical imports are projected to reach approximately $213 billion in 2024, tripling over the past decade, with over 20% coming from Asia [3] - The new tariffs may lead to increased drug prices for U.S. consumers, as the average spending on prescription drugs is already about twice that of other developed countries [3] - Pharmaceutical companies warn that the tariffs could hinder drug development and raise prices [3] Concerns from Small and Generic Drug Manufacturers - Smaller pharmaceutical companies producing niche drugs may face significant challenges, as they might not afford to relocate production to the U.S. [3] - The potential for supply disruptions exists, particularly for patented drugs that lack alternatives [3] Indian Generic Drug Industry - Indian pharmaceutical companies are currently not directly affected by the tariffs on generic drugs, but there are concerns about future expansions of the tariff scope [4][5] - India supplies over one-third of the U.S. pharmaceutical market, with exports projected to reach $27.9 billion in the 2024 fiscal year [5][6] European Pharmaceutical Industry Response - The European pharmaceutical sector has expressed strong opposition to the tariffs, warning of increased production costs and potential disruptions to international supply chains [7][8] - Germany's pharmaceutical industry heavily relies on the U.S. market, with exports valued at €27 billion in 2024, making the new tariffs particularly concerning [7] - Some companies are taking proactive measures, such as Bayer's commitment to constructive cooperation with the U.S. government [8] Risk of Drug Shortages and Price Increases - The tariffs could exacerbate existing drug shortages in Europe, with reports indicating that around 450 drugs are currently out of stock in Germany [9] - Companies may consider raising prices in European markets to offset losses from the U.S. market, as seen with Sanofi and Eli Lilly [9]

Core Insights - Regeneron Pharmaceuticals has received FDA approval for a label extension of its cholesterol drug Evkeeza for children aged one to less than five years with homozygous familial hypercholesterolemia (HoFH) [1][7] - The approval is based on clinical efficacy and safety data from six children with HoFH [2][7] - Evkeeza generated sales of $72.1 million in the U.S. during the first half of 2025 [3][7] Drug Development and Commercialization - Evkeeza was initially approved in 2021 for adults and adolescents aged 12 years and older with HoFH, followed by approval for children aged five to 11 years [2] - Regeneron is responsible for the development and distribution of Evkeeza in the U.S., while Ultragenyx Pharmaceutical is responsible for commercialization outside the U.S. [4][7] Financial Performance - Eylea, Regeneron's lead drug, has faced declining sales due to competition from Roche's Vabysmo, impacting the company's overall revenue [5][6] - Eylea HD sales surged 29% in the second quarter due to increased demand [9] Portfolio Diversification - Regeneron is working to diversify its portfolio, with solid sales from Dupixent contributing to its top line [10] - Recent progress in the oncology portfolio, including Libtayo and Lynozyfic, is expected to enhance growth [11]

GSK (GSK) stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year. She will be succeeded by Luke Miels, the current chief commercial officer. Prior to joining GSK in 2017, Miels has worked across the globe at AstraZeneca (AZN), Roche (RHHBY) and Sanofi (SNY). Walmsley has led GSK for nine years and says it's time to hand the reins over to someone new. "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe t ...